Brief: Medmix AG FY 2024 Guidance Organic Revenue Growth Of 4% To 6%,
Feb 22 (Reuters) - medmix AG MEDX.S :
* FY 2024 GUIDANCE: ORGANIC REVENUE GROWTH OF 4% TO 6%,
* MANAGEMENT EXPECTS HIGHER-THAN-USUAL CAPITAL EXPENDITURE
IN 2023
(13.7% OF REVENUE) TO RETURN TO ROUGHLY 9% OF GROUP REVENUE IN
2024
* FY EBIT CHF 16 MILLION, DOWN 18.5%
* FY EBITDA CHF 74.4 MILLION, UP 5.2%
Further company coverage: MEDX.S
((Reuters.Briefs@thomsonreuters.com;))